

降钙素原在恶性肿瘤患者感染诊治中的应用进展

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2020年03期 页码: 521-524 栏目: 综述 出版日期: 2019-12-26

Title: Progress in the application of procalcitonin in the diagnosis and treatment of infection in patients with malignant tumors

作者: 乌日汗; 王士勇

中国医科大学附属第四医院第三肿瘤内科暨生物治疗科, 辽宁 沈阳 110032

Author(s): Wu Rihan; Wang Shiyong

Department of Third Oncology and Biotherapy, the Fourth Affiliated Hospital of China Medical University, Liaoning Shenyang 110032, China.

关键词: 降钙素原; 恶性肿瘤; 感染

Keywords: procalcitonin; malignant tumor; infection

分类号: R730.5

DOI: 10.3969/j.issn.1672-4992.2020.03.041

文献标识码: A

摘要: 探讨降钙素原在恶性肿瘤患者感染诊治中的应用进展, 总结近年来文献对降钙素原在良、恶性疾病的临床应用状况, 结果显示降钙素原对感染性疾病的诊断有重要意义, 在恶性肿瘤患者的感染诊治中有较好的指示作用。

Abstract: To explore the application of procalcitonin in the diagnosis and treatment of infection in patients with malignant tumors, summarize the recent clinical application of procalcitonin in benign and malignant diseases. The results show that procalcitonin has important significance in the diagnosis of infectious diseases, and has a good indication in the diagnosis and treatment of infection in patients with malignant tumors.

参考文献/REFERENCES

- [1] Jacobs JW, Lund PK, Potts Jr Jt, et al. Procalcitonin is a glycoprotein [J]. *J Biol Chem*, 1981, 256(6):2803-2807.
- [2] LIN L, SUN XF, TAN XL, et al. The value of serum procalcitonin (PCT) in identifying the cause of fever in patients with cancer [J]. *Practical Journal of Cancer*, 2009, 24(01):48-51. [林琳, 孙晓非, 谭肖鹏, 等. 血清降钙素原 (PCT) 鉴别肿瘤患者发热原因的价值探讨 [J]. *实用癌症杂志*, 2009, 24(01):48-51.]
- [3] Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentration in patients with sepsis and infection [J]. *Lancet*, 1993, 341(8844):515-518.
- [4] Maruna P, Nedelnikova K, Gurlieh R. Physiology and genetics of procalcitonin [J]. *Physiol Res*, 2000, 49(Suppl): 57-61.
- [5] Whang KT, Vath SD, Becket KL, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis [J]. *Shock*, 2000, 14(1): 73-78.
- [6] Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects [J]. *J Clin Endocrinol Metab*, 1994, 79(6):1605-1608.
- [7] Procalcitonin emergency clinical application expert consensus group. Procalcitonin (PCT) emergency. Expert consensus on clinical application [J]. *Chinese Journal of Emergency Medicine*, 2012, 21(9):944-951. [降钙素原急诊临床应用专家共识组. 降钙素原 (PCT) 急诊临床应用的专家共识 [J]. *中华急诊医学杂志*, 2012, 21(9):944-951.]
- [8] DING H, ZHU XC, CHI JY, et al. The value of NAP, PCT and hs-CRP detection in identifying infection types [J]. *Laboratory Medicine*, 2017, 32(10):894-897. [丁红, 朱星成, 迟锦瑜, 等. NAP、PCT、hs-CRP 检测在鉴别感染类型中的价值 [J]. *检验医学*, 2017, 32(10):894-897.]
- [9] Guo SY, Zhou Y, Hu QF, et al. Procalcitonin is a marker of gram-negative bacteremia in patients with sepsis [J]. *American Journal of the Medical Sciences*, 2015, 349(6):499-504.
- [10] Brutsaert EF, Gersten AJ, Tassler AB, et al. Medullary thyroid cancer with undetectable serum calcitonin [J]. *Journal of Clinical Endocrinology & Metabolism*, 2015, 100(2):337-41.
- [11] Bugalho MJ, Madureira D, Domingues R, et al. Medullary thyroid carcinoma preferentially secreting procalcitonin [J]. *Thyroid*, 2014, 24(7):1190-1191.
- [12] Kaczka K, Mikosiński S, Fendler W, et al. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection [J]. *Advances in Clinical & Experimental Medicine*, 2012, 21(2):169-178.

- [13] Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer [J]. *Journal of Clinical Endocrinology & Metabolism*, 2014, 99(8):2986-2994.
- [14] Cate CC, Pettengill OS, Sorenson GD. Biosynthesis of procalcitonin in small cell carcinoma of the lung [J]. *Cancer Res* 1986, 46(2):812-818.
- [15] M Patout, M Salaün, V Brunel, et al. Thiberville. Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers [J]. *Clinical Biochemistry*, 2014, 47(18):263-267.
- [16] Avrillon V, Locatellisánchez M, Folliet L, et al. Lung cancer may increase serum procalcitonin level [J]. *Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious)*, 2015, 15(1):57-63.
- [17] Hagiya H, Matsui T, Kitamura T, et al. Pancreatic neuroendocrine tumor abnormally secreting procalcitonin [J]. *Pancreas*, 2017, 46(1):e7-e9.
- [18] Chen L, Zhang Y, Lin Y, et al. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system [J]. *Clinical Biochemistry*, 2017, 50(18):982-987.
- [19] YE Q, CHEN Y, LUO LQ, et al. The value of serum procalcitonin and C-reactive protein in identifying the cause of fever in cancer patients [J]. *International Journal of Laboratory Medicine*, 2014, 35(19):2604-2606. [叶倩, 陈燕, 罗玲清, 等. 血清降钙素原及C反应蛋白在鉴别肿瘤患者发热原因中的价值 [J]. *国际检验医学杂志*, 2014, 35(19):2604-2606.]
- [20] CHEN YK, DENG H, CAI SN, et al. Clinical study on early diagnosis of infection and tumor heat in patients with advanced tumors [J]. *Chinese Journal of Nosocomiology*, 2016, 26(12):2721-2723. [陈银葵, 邓欢, 蔡思娜, 等. 肿瘤晚期患者感染与肿瘤热早期诊断的临床研究 [J]. *中华医院感染学杂志*, 2016, 26(12):2721-2723.]
- [21] Zhao Z, Li X, Zhao Y, et al. Role of C-reactive protein and procalcitonin in discriminating between infectious fever and tumor fever in non-neutropenic lung cancer patients [J]. *Medicine (Baltimore)*, 2018, 97(33):e11930.
- [22] GUO F, HUO YS, FENG M, et al. Study of procalcitonin in the diagnosis of fever in patients with malignant tumors [J]. *International Journal of Laboratory Medicine*, 2017, 38(9):1186-1189. [郭凡, 霍怡杉, 封敏, 等. 降钙素原在恶性肿瘤患者发热诊断中的研究 [J]. *国际检验医学杂志*, 2017, 38(9):1186-1189.]
- [23] ZHANG JY, YU Z, JIA L, et al. Clinical value of procalcitonin in the differential diagnosis of bacterial bloodstream infection in patients with cancer [J]. *Chinese Journal of Nosocomiology*, 2017, 27(2):288-291. [张静雅, 于珍, 贾丽, 等. 降钙素原在肿瘤患者细菌血流感染鉴别中的临床价值研究 [J]. *中华医院感染学杂志*, 2017, 27(2):288-291.]
- [24] Vincenzi B, Fioroni I, Pantano F, et al. Procalcitonin as diagnostic marker of infection in solid tumors patients with fever [J]. *Scientific Reports*, 2016(6):28090.
- [25] LU YJ, LU S. Application of procalcitonin in patients with non-neutrophilic tumor fever [J]. *Chinese Contemporary Medicine*, 2013, 20(15):51-52. [陆粤就, 陆森. 降钙素原在非中性粒细胞减少肿瘤发热患者中的应用研究 [J]. *中国当代医药*, 2013, 20(15):51-52.]
- [26] ZHANG LP. The value of serum procalcitonin detection in the diagnosis of neutropenia with infection after solid tumor chemotherapy [J]. *Journal of Clinical Medicine in Practice*, 2014, 18(15):187-189. [张丽萍. 血清降钙素原检测在实体瘤化疗后粒细胞减少伴感染诊断中的价值 [J]. *实用临床医药杂志*, 2014, 18(15):187-189.]
- [27] ZHANG ZW, SHEN LH, FU FM, et al. Clinical significance of procalcitonin in patients with chemotherapy-induced neutropenia and fever [J]. *Chinese Journal of Cancer*, 2016, 26(3):263-267. [张忠伟, 申丽华, 傅凤鸣, 等. 降钙素原在化疗致粒细胞减少伴发热患者中的临床意义 [J]. *中国癌症杂志*, 2016, 26(3):263-267.]
- [28] Murat Sedef A, Kose F, Taner Sumbul A, et al. Prognostic value of procalcitonin in infection-related mortality of cancer patients [J]. *Journal of BUON: Official Journal of Balkan Union of Oncology*, 2016, 21(3):740-744.
- [29] ZHANG H, ZHOU WB, ALMS. The differential significance of procalcitonin and C-reactive protein in patients with malignant tumor fever [J]. *Journal of The Central University for Nationalities (Natural Sciences)*, 2016, 25(02):68-70. [张华, 周文斌, 阿里穆斯. 降钙素原与C-反应蛋白在恶性肿瘤发热患者中的鉴别意义 [J]. *中央民族大学学报(自然科学版)*, 2016, 25(02):68-70.]
- [30] QIAN X, MA JF. Clinical value of combined detection of serum procalcitonin and C-reactive protein in the diagnosis of early infection in patients with malignant tumors [J]. *Chinese Journal of Laboratory Diagnosis*, 2017, 21(03):399-402. [钱香, 马建锋. 血清降钙素原与C-反应蛋白联合检测对恶性肿瘤患者早期感染诊断的临床价值 [J]. *中国实验诊断学*, 2017, 21(03):399-402.]
- [31] WANG Y, TONG FZ, TONG J, et al. The application value of procalcitonin, hypersensitive C-reactive protein and white blood cell count in the diagnosis of malignant tumor with infection [J]. *Contemporary Medicine*, 2017, 23(33):41-43. [王岩, 佟凤芝, 佟静, 等. 降钙素原、超敏C反应蛋白、白细胞数在恶性肿瘤伴感染诊断中的应用价值 [J]. *当代医学*, 2017, 23(33):41-43.]

备注/Memo: -

更新日期/Last Update: 1900-01-01